Multidrug-resistant tuberculosis (MDR-TB) in India: An attempt to link biosocial determinants

Journal of Public Health Policy

Volumn 26, Issue 1, 2005, Pages 96-114

  Atre, Sachin R ^b   Mistry, Nerges F ^a  

^a Foundation for Research in Community Health India   (India)

^b NONE

Author keywords

Acquired; Behavioral; Drug resistance; Medical; Primary; Socio cultural

Indexed keywords

TUBERCULOSTATIC AGENT;

COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; DRUG COST; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HUMAN; INDIA; MULTIDRUG RESISTANCE; PREVALENCE; PUBLIC HEALTH SERVICE; REVIEW; SHORT COURSE THERAPY; SOCIAL ASPECT; SOCIOECONOMICS; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; DELIVERY OF HEALTH CARE; DRUG INDUSTRY; DRUG RESISTANCE, BACTERIAL; EPIDEMIOLOGY, MOLECULAR; HEALTH POLICY; HUMANS; INDIA; POVERTY; PREVALENCE; RISK FACTORS; SEX FACTORS; SOCIOECONOMIC FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH;

EID: 18244374174     PISSN: 01975897     EISSN: None     Source Type: Journal    
DOI: 10.1057/palgrave.jphp.3200014     Document Type: Review

References (73)

1. World Health Organization. Global Tuberculosis Control. WHO/CDS/ TB/2OO2.295. World Health Organization: Geneva; 2002.
2. Floyd K, Blanc L, Raviglione M. Resources required for global tuberculosis control. Science. 2002;295:2040-1.
3. Mckeown T, Record RG. Reasons for decline in mortality in England and Wales in the nineteenth century. Population Studies. 1962;16:94-122.
4. McFarlane N. Hospitals, housing and tuberculosis in Glasgow, from 1911-1951. Social History Med. 1989;2:59-85.
5. Grange JM, Gandy M, Farmer PE, Zumla A. Historical declines in tuberculosis: nature, nurture and the biosocial model. Int J Tuberculosis Lung Dis. 2001;5:208-12
6. Wilkinson RJ, Llewelyn M, Toossi Z, Patel P, Pasvol G, Lalvani A, et al. Influence of Vitamin D deficiency and Vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in West London: a case-control study. Lancet. 2000;355:618-21.
7. Gupta R, Kim JY, Espinal MA, Caudron J, Pecoul B, Farmer PE, et al. Responding to market failures in tuberculosis control. Science. 2001:293:1049-51.
8. Espinal M. Global trends in resistance to and tuberculosis drugs. N Engl J Med. 2001:344:1294-303.
9. A History of Tuberculosis Chemotherapy. Available at http://www. molbio.princeton.edu/courses/mb427/2000/projects/0006, accessed 1 June 2004.
10. Farmer P, Kim JY. Community based approaches to the control of multi drug resistant tuberculosis: Introducing DOTS-Plus. BMJ. 1998;317: 671-4.
11. Chaisson R. The Russian Correction: An Evolving Paradigm for TB Control. Available at www.hopkins-tb.org, accessed 20 May 2004.
12. WHO/IUATLD. Global Project on Anti-Tuberculosis Drug Resistance in the World. Prevalence and Trends. Anti-Tuberculosis Drug Resistance in the World, Report No.2 WHO/CDS/TB 2000.278. World Health Organization: Geneva; 2000.
13. WHO/IUATLD. Global Project on Anti-tuberculosis Drug Resistance Surveillance. Anti-Tuberculosis Drug Resistance in the World, Report No. 3. World Health Organization: Geneva; 2004.
14. Paramsivan CN, Bhaskaran K, Venkataram P, Chandrasekaran V, Narayanan PR. Surveillance of drug resistance in tuberculosis in the state of Tamilnadu. Indian J Tuberculosis. 2000:47:27-33.
15. Paramasivan CN, Venkataraman P, Chandrasekaran V, Bhat S, Narayanan PR. Surveillance of drug resistance in tuberculosis in two districts of South India. Int J Tuberculosis Lung Dis. 2002;6:479-84.
16. Udwadia ZF, Hakimayan A, Rodrigues C, Jillisgar T, Mehta A. A profile of drug-resistant tuberculosis in Bombay. Chest. 1996; 110:228S.
17. Birdy T, Dholakia Y, D'Souza D, Oza BB, Hira S, Antia NH. A preliminary report on initial mycobacterial drug resistance in HIV-TB dual infection in Mumbai. Selections from BMJ. 2002;18:879-81.
18. Farmer P. Social inequalities and emerging infectious diseases. Emerging Infect Dis. 1996;2:259-67.
19. McKeegan KS, Borges-Walmsley MI, Walmsley AR. Microbial and viral drug resistance mechanisms. Trends Microbiol. 2002;10:S8-14.
20. Williams R. Antimicrobial resistance: the facts. Essential Drugs Monit. 2000;28/29:7-8.
21. Hoffner SE, Heurlin N, Petrini B, Srenson SB, Kallerius G. M Avium complex develops resistance to synergistically active drug combinations during infection. Eur Respir J. 1994;7:247-50.
22. Dye C, Williams BG, Espinal M, Raviglione MC. Erasing the World's slow stain: strategies to beat multi drug-resistant tuberculosis. Science. 2002;295:2042-6.
23. Billington OJ, McHugh TD, Gillespie SH. Physiological cost of rifampicin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1999;43:1866-9.
24. Glynn JR, Whiteley J, Bifani PJ, Kermer K, Soolingen DV. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerging Infect Dis. 2002;8(8):843-9.
25. Mistry NF, Iyer AM, D'souza DTB, Taylor GM, Young DB, Antia NH. Spoligotyping of Mycobacterium tuberculosis isolates from multiple drug-resistant tuberculosis patients from Bombay, India. J Clin Microbiol. 2002;40(7):2677-80.
26. Almeida D, Rodrigues C, Udawadia ZF, Lalvani A, Gothi GD, Mehta P, et al. Incidence of multidrug-resistant tuberculosis in urban and rural India and implications for prevention. Clin Infect Dis. 2003;36:e152-4.
27. Kenyon TA, Mwasekaga MJ, Huebner R, Rumisha D, Bikin N, Maganu E. Low levels of drug resistance amidst rapidly increasing tuberculosis and Human Immunodeficiency Virus co-epidemics in Botswana. Int J Tuberculosis Lung Dis. 1999:3:4-11.
28. Gordin FM, Nelson ET, Matts JP, Cohn DL, Ernst J, Benator D, et al. The impact of human immuno deficiency virus infection on drug resistant tuberculosis. Am J Respir Crit Care Med. 1996;154: 1478-83.
29. Farmer P. Immodest claims of causality In: Infections and Inequalites: The Modern Plagues. University of California Press: Berkeley, CA; 1999. pp. 231-61.
30. Byrd RP. Malnutrition and pulmonary tuberculosis. Clin Infect Dis. 2002;35:633-4.
31. Uplekar MW, Rangan S. Tackling TB: Search for Solutions. The Foundation for Research in Community Health: Bombay; 1996.
32. Mistry NF, Antia NH. Obstacles to the control of MDR-TB in India. Health Administrator. 2003;XVI/2:137-42.
33. Atre SR, Kudale AM, Morankar SN, Rangan SG, Weiss MG. Cultural concepts of tuberculosis and gender among the general population without tuberculosis in rural Maharashtra, India. Tropical Med Int Health. 2004;9(11):1228-38.
34. Morankar S, Deshmukh D. Socio-cultural Aspects of Tuberculosis Among Women: Implications for Delivery of Health Services. Foundation for Research in Community Health: Pune; 2001.
35. Uplekar MW, Pathania V, Raviglione M. Private practitioners and public health: weak links in tuberculosis control. Lancet. 2001;5358:912-6.
36. National Council of Applied Economic Research. Household Survey of Health Care Utilization and Expenditure, Working paper no. 53. National Council of Applied Economic Research: New Delhi; 1995.
37. Duggal R, Nandraj S, Shetty S. State Sector Health Expenditures (1951-85). The Foundation for Research in Community Health: Bombay; 1992. pp. 11.
38. Uplekar MW, Shepard DS. Treatment of tuberculosis by private general practitioners in India. Tubercle. 1991;72:284-90.
39. Kaul S. An Observational Study of RNTCP and DOTS Strategy in Three Districts. Voluntary Health Association of India: New Delhi; 1998.
40. Phadake A. Drug Supply and Use: Towards a Rational Policy in India. Sage Publications: India; 1998.
41. Urban DOTS Project (UDP). Available at http://wwwtbcindiaorg/pdfs Urban%20DOTS%20Project%20in%204%20cities%20(Proposed).pdf.
42. Gilson L, Jaffar S, Mwankusye S, Tenscher T. Assessing prescribing practice: a Tanzanian example. Int J Health Plann Manage. 1993;8: 37-58.
43. Uppal R, Sarkar U, Giriyappanavar CR, Kacker V. Antimicrobial drug use in primary health care. J Clin Epidemiol. 1993;46(7):671-3.
44. World Health Organization. Traditional Medicine, the World Drug Situation. World Health Organization: Geneva, 1998; pp. 5-6.
45. Espinal M, Zaleski R. TB control and access to second line drugs - better model needed. Bull of World Health Organization. 2002;80(6): 495-6.
46. Medecins Sans Frontieres (MSF). Running Out of Breath? TB Care in the 21st Century. Available at http://www.msf.org, accessed 18 March 2004.
47. World Health Organization. WHO Involvement in Disease Surveillance in India. Integrated Disease Surveillance Project (IDSP). Available at http://www.whoindia.org/CDS/DiseaseSurveillance/DS-main. htm, accessed 5 October 1004.
48. Antia NH. Global policies and peoples' health. Nat Med J India. 1993;6(1):1-2.
49. Chowdhury Z. The Global Drug Situation. The Politics of Essential Drugs. Vistaar Publications: New Delhi; 1996. pp. 20-1.
50. Lall S. The Multinational Corporation. Macmillan: London; 1980.
51. Bhargava A. Tremendous variations in drug prices in the Indian pharmaceutical market. In: Locost, Impoverishing the Poor: Pharmaceuticals and Drug Pricing in India. Vadodara: Gujarat; 2004. pp. 37-45.
52. Riggs TL. Research and development costs for drugs: commentary. Lancet. 2004;363:184.
53. World Health Organization. Macroeconomics and Health: Investing in Health for Economic Development. Presented to WHO Director General. World Health Organization: Geneva; 2001.
54. World Health Organization. DOTS Plus Strategy. Available at http:// www.stoptb.org, accessed 22 March 2004.
55. Gupta R, Irwin A, Raviglione MC, Kim JY. Scaling-up treatment for HIV/AIDS: Lessons learned from multidrug-resistant tuberculosis. Lancet. 2004;363:320-4.
56. Sterling T, Lehman H, Friden T. Impact of DOTS compared with DOTS plus on multidrug-resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ. 2003;326:574-9.
57. Khamar et al. (personal communication).
58. Catalani E. Review of Indian market of anti-tuberculosis drugs: focus on the utilization of rifampicin based products. Int J Tuberculosis Lung Dis. 1999;3:289-91.
59. Central TB Division. Directorate General of Health Services Ministry of Health and Family Welfare. TB Control in India. Nirman Bhavan: New Delhi; 2001. Available at http://www.tbcindia.org.
60. Styblo K, Bumgarner JR. Tuberculosis can be Controlled with Existing Technologies: Evidence. Tuberculosis Surveillance Research Unit: The Hague; 1991. pp. 60-72.
61. Elzinga G, Raviglione MC, Maher D. Scale up: meeting targets in global tuberculosis control. Lancet. 2004;363.-814-9.
62. Central TB Division. Directorate General of Health Services Ministry of Health and Family Welfare. TB Control, India, Nirman Bhavan: New Delhi; 2004. Available at http://www.tbcindia.org/documents. asp/TBindia2004.pdf, accessed 7 October 2004.
63. World Health Organization. Global DOTS Expansion Plan (GDEP). Progress in TB Control in High-Burden Countries, WHO/CDS/STB/ 2001.11. World Health Organization: Geneva; 2001.
64. Volmin KJ, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database System Rev. 2003;1:4.
65. Fox W. Self-administration of medicaments. A review of published work and a study of the problems. Bull Int Union Tuberculosis. 1961;31:307-31.
66. Mathema B, Pande SB, Jochem K, Houston RA, Smith I, Bom DS. Tuberculosis treatment in Nepal: a rapid assessment of Government centers using different types of patient supervision. Int J Tuberculosis Lung Dis. 2001;5:912-9.
67. Manabe YC, Bishai WR. Latent Mycobacterium tuberculosis - persistence, patience, and winning by waiting. Nature Med. 2000;6:1327-9.
68. Narita M, Stambaugh JJ, Hollender ES, Jones D, Pitchenik AE, Ashkin D. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis. Clin Infect Dis. 2000;30: 779-83.
69. Weiss MG, Ramkrishna J. Stigma Interventions and Research for International Health. Background Paper. Stigma and Global Health: Developing a Research Agenda, An International Conference, 2001; September 5-7; Bethesda, MA, USA.
70. Maher D, Uplekar MW, Blanc L, Raviglione MC. Treatment of tuberculosis: Concordance is a key step. Br Med J. 2003;327:822-3.
71. Uplekar MW, Rangan S. Private doctor and tuberculosis control in India. Tubercle Lung Dis. 1993;74:332-7.
72. Walton DA, Farmer PE, Lambert W, Leandre F, Koenig SP, Mukherjee JS. Integrated HIV prevention and care strengthens primary health care: lessons from rural Haiti. J Public Health Policy. 2004;25(2): 137-58.
73. Keusch GT. Spreading effective AIDS care in poor countries. Thoughts on the Partners-in-Health/Zanmi Lasante Experience in Haiti. J Public Health Policy. 2004;25(2):159-61.